Maple Syrup Urine Disease — a branched-chain amino acid metabolic emergency where genotype determines the difference between classic lethal disease and mild intermittent forms manageable with dietary adjustment.
Whole genome sequencing evaluates all three BCKD complex genes — BCKDHA, BCKDHB, and DBT — identifying the specific variant combination that determines disease severity and long-term dietary leucine tolerance.
Maple Syrup Urine Disease
Maple syrup urine disease (MSUD) is an autosomal recessive disorder of branched-chain amino acid (BCAA) metabolism caused by deficiency of the branched-chain α-ketoacid dehydrogenase (BCKD) complex. Three genes encode the catalytic subunits: BCKDHA (E1α, chromosome 19q13.2), BCKDHB (E1β, chromosome 6q14.1), and DBT (E2, chromosome 1p21.2). BCKD complex deficiency causes accumulation of leucine, isoleucine, and valine and their corresponding α-ketoacids, producing the characteristic maple syrup odor in urine and cerumen. Classic MSUD affects approximately 1 in 185,000 newborns worldwide, with dramatically elevated prevalence in Old Order Mennonite populations (approximately 1 in 176 births).
Classic MSUD presents as a neonatal emergency: affected newborns appear normal at birth but develop poor feeding, lethargy, and a distinctive sweet odor within 2-3 days. Without immediate treatment, progressive encephalopathy leads to cerebral edema, coma, and death within the first weeks of life. The primary toxic metabolite is leucine — plasma leucine levels are the critical monitoring parameter. Treatment requires immediate BCAA-free formula, lifelong dietary leucine restriction, and emergency metabolic protocols during illness-related catabolism. Liver transplantation provides definitive metabolic correction and is increasingly performed in early childhood.
Variant forms — intermediate, intermittent, and thiamine-responsive MSUD — present later in life with episodic metabolic crises triggered by illness or protein intake. These milder phenotypes retain 3-30% residual BCKD enzyme activity and are determined by specific genotype combinations. Thiamine-responsive MSUD (primarily BCKDHB variants) can be partially managed with pharmacological thiamine supplementation, reducing dietary restriction burden. Identifying the specific MSUD genotype determines disease classification, dietary management intensity, and thiamine responsiveness.
Thiamine-responsive MSUD — primarily caused by specific BCKDHB variants — retains partial enzyme activity that can be enhanced with high-dose thiamine supplementation, reducing the severity of dietary restriction required.
Newborn screening detects elevated BCAAs but does not identify which gene is affected or predict disease severity. Molecular genotyping determines classic vs. intermediate vs. thiamine-responsive forms — directly affecting treatment approach.
The specific BCKD gene and variant determine whether thiamine supplementation can reduce dietary restriction
Thiamine-responsive MSUD — primarily associated with specific BCKDHB missense variants — retains sufficient residual enzyme activity that high-dose thiamine (100-300mg/day) can meaningfully increase BCKD complex function. For these patients, thiamine supplementation allows higher dietary leucine tolerance, reducing the burden of lifelong BCAA-restricted diet. Without molecular genotyping, thiamine responsiveness must be determined empirically through a therapeutic trial, which delays optimization of the dietary regimen. Whole genome sequencing identifies the specific gene and variant, enabling immediate classification of thiamine-responsive potential.
Carrier screening in high-prevalence populations prevents neonatal metabolic crises before they occur
In Old Order Mennonite communities, MSUD carrier frequency approaches 1 in 7 — meaning approximately 1 in 176 births is affected. The Mennonite founder mutation (BCKDHA p.Tyr438Asn) accounts for the vast majority of alleles in these communities. Carrier screening identifies at-risk couples before pregnancy, enabling prenatal diagnosis and ensuring delivery at centers with immediate metabolic management capability. In broader populations, carrier frequency is approximately 1 in 200-300 — low enough that targeted screening is rarely performed, but common enough that unexpected MSUD births occur regularly. Whole genome sequencing provides carrier status as part of comprehensive preconception genetic evaluation.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for Maple Syrup Urine Disease and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
